精神医学51巻1号

2009年01月発行

記事購入ページに移動

展望

5-HT_1A受容体アゴニストによる精神障害の治療

著者： 融道男¹²

所属機関： ¹メンタルクリニックおぎくぼ ²東京医科歯科大學

ページ範囲：P.6 - P.14

　セロトニン(5-HT)受容体のうち，精神科臨床においては，5-HT_2A，5-HT_2Cと5-HT_1A受容体が重要であると考えられる³⁵⁾。今回は5-HT_1A受容体部分的アゴニストのうち3種の薬剤を選んで，精神障害に対して治療効果を得た症例の検討を含めて記述する。薬剤は，タンドスピロン(Ki＝27nM)，ペロスピロン(Ki＝2.9nM)，アリピプラゾール(Ki＝5.6nM)であり，すべてわが国で創薬されたものである。これらの薬剤は5-HT_1A受容体に高い親和性を持つが，5-HT活性比は60～70％程度であることから部分的アゴニストと呼ばれる。

参考文献

1) Arborelius L, Nomikos GG, Hacksell U, et al：[R]-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 148：465-466, 1993

2) Ase A, Amdiss F, Hébert C, et al：Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin-1A receptors. J Neural Transm 106：75-105, 1999

3) Assié MB, Ravailhe V, Faucillon V, et al：Constrasting contribution of 5-hydrotryptamine 1A receptor activation to neurochemical profile of novel antipsychotics：Frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315：265-272, 2005

4) Bantick RA, Deakin JFW, Grasby PM：The 5-HT1A receptor in schizophrenia：A promising target for novel atypical neuroleptics?　J Psychopharmacol 15：37-46, 2001

5) Bantick RA, Montgomery A, Bench CJ, et al：A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol 18：346-354, 2004

6) Barret JE, Vanover KE：5-HT receptors as targets for the development of novel anxiolytic drug：Models, mechanisms and future direction. Psychopharmacol 112：1-12, 1993

7) Boldrini M, Underwood MD, Mann JJ, et al：Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. J Psychiat Res 42：433-442, 2008

8) Burnet PW, Eastwood SL, Harrison PJ：5-HT1A and 5-HT2A receptor mRNA and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacol 15：442-455, 1996

9) Burnet PW, Eastwood SL, Harrison PJ：[3H] WAY-100635 for 5-HT1A receptor audioradiography in human brain：A comparison with [3H]-8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30：565-574, 1997

10) Castner S, Williams G, Goldman-Rakic PS：Reversal of antipsychotic induced working memory deficits by short-term dopamineD1 receptor stimulation. Science 287：2020-2022, 2000

11) De Vry J：5-HT1A receptor agonists：Recent developments and controversial issues. Psychopharmacology 121：1-26, 1995

12) De Vry J, Schreiber R, Melon C, et al：5-HT1A Receptors are differentially involved in the anxiolytic-and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur Neuropsychopharmacol 14：487-495, 2004

13) Dimitriou EC, Dimitriou CE：Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 18：465-469, 1998

14) Drevets WC, Thase ME, Moses-Kolko EL, et al：Serotonin-1A receptor imaging in recurrent depression：Replication and literature review. Nucl Med Biol 34：865-877, 2007

15) Eison MS：Azapirones：Mechanism of action in anxiety and depression. Drug Ther(Supl)：3-8, 1990

16) Gobert A, Rivet JM, Cistarelli JM, et al：Buspirone enhances duloxetine-and fluoxetine-induced increases in dialysate level of dopamine and noradrenaline, but not serotonin, in frontal cortex of freely rats. J Neurochem 68：1326-1329, 1977

17) Goff DC, Midha KK, Brotman AW, et al：An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11：193-197, 1991

18) Hagiwara H, Fujita Y, Ishima T, et al：Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of antipsychotic drug prospirone：Role of serotonin 5-HT 1A receptors. Eur Neuropsychopharmacol 18：448-454, 2008

19) Hashimoto T, Nishino N, Nakai H, et al：Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48：355-363, 1991

20) Hamik A, Oksenberg D, Fischlette C, et al：Analysis of tandospirone(SM-3997)interactions with neurotransmitter receptor binding sites. Biol Psychiatry 28：99-109, 1990

receptor activation：A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76：1521-1531, 2001

22) 井上猛，小山司：SSRIで十分に改善せずタンドスピロン併用により寛解に至った単極性うつ病の1例．精神医学 44：285-287，2002

23) 稲永和豊，西彰五郎：Tandospironeと選択性セロトニン再取り込み阻害剤(SSRI)との併用の試み．臨精薬理 5(増刊)：31-41，2002

receptors. Biogenic Amines 18：307-317, 2004

25) Jacobson FM：Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 52：217-220, 1991

26) Joffe RT, Schuller DR：An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 54：269-271, 1993

27) Kalkman H, Newman V, Nozulak J, et al：Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat. Eur J Pharmacol 343：201-207, 1998

28) Kapur S, Remington G：Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153：466-476, 1996

29) Kato T, Hirose A, Ohno Y, et al：Binding profile of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol 54：478-481, 1990

30) 工藤義雄，中嶋照夫，斎藤正巳，他：セロトニン・ドーパミン受容体拮抗薬(SDA)塩酸perospironeの精神分裂病に対する臨床評価―塩酸mosapramineを対照薬として第III相試験．臨床評価 24：207-248，1997

31) 姜昌勲，杉原克比古，五十嵐潤，他：タンドスピロンとSSRIによる併用療法が奏効した強迫性障害の1例．精神医学 44：299-301，2002

32) Leysen JE, Gommeren W, Schotte A：Serotonin receptor subtypes：Possible roles and implications in antipsychotic drug action. In：Kane JM, Möller HI, Awouters F eds. Serotonin in Antipsychotic Treatment. Mechanisms and Clinical Practice. Marcel Dekker, New York, pp51-75, 1996

receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 41：494-508, 1992

34) Meller E, Goldstein M, Bohmaker K：Receptor reserve for 5-hydroxy-tryptamine 1A-mediated inhibition of serotonin synthesis：Possible relationship to anxiolytic properties of 5-hydroxytryptamine 1A agonists. Mol Pharmacol 37：231-237, 1990

35) Meltzer HY, Li Z, Huang M, et al：Serotonergic mechanism in schizophrenia：Evolution and current concepts. Curr Psychosis Therap Rep 4：12-19, 2006

receptors. J Pharmacol Exp Ther 295：853-861, 2000

37) 村崎光邦，山下格，町山幸輝，他：新規抗精神病薬　塩酸perospironeの精神分裂病に対する前期第2相試験．基礎と臨床 31：2159-2179，1997

S]GTPγS binding study. Eur J Pharmacol 355：245-256, 1998

39) Newman-Tancredi A, Assié MB, Leduc N, et al：Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors：Affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8：341-356, 2005

S] GTPγS binding in rat hippocampal membranes. Clin Exp Pharmacol Physiol 34：462-466, 2007

41) Odagaki Y, Fuxe K：Pharmacological characterization of the 5-hydroxy-tryptamine-1A receptor-mediated activation of high-affinity GTP hydrolysis in rat hippocampal membranes. J Pharmacol Exp Ther 274：337-344, 1995

42) Onrust SV, McClellan K：Perospirone. CNS Drugs 15：329-337, 2001

43) Pae CU, Seretti A, Patkar AA, et al：Aripiprazole in the treatment of depressive and anxiety disorders. A review of current evidence. CNS Drugs 22：367-388, 2008

44) Puig MV, Artigas F, Celada P：Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo：Involvement of serotonin and GABA. Cereb Cortex 15：1-14, 2005

45) Richelson E, Souder T：Binding of antipsychotics drug to human receptors. Focus on newer generation compounds. Life Sci 68：29-39, 2000

46) Roth BL, Scheffer D, Potkin SG：Atypical antipsychotic drug actions：Unitary or multiple mechanisms for "atypicality"?　Clin Neuroci Res 3：108-117, 2005

47) Shapiro DA, Renocks S, Arrington E, et al：Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 28：1400-1411, 2003

receptors. Beh Brain Res 191：26-31, 2008

49) Sovner R, Parnell-Sovner N：Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmacol 9：61-62, 1989

50) Stockmeier CA, Shapiro LA, Dilley GE, et al：Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci 18：7394-7401, 1998

51) Sumiyoshi T, Stockmeier CA, Overholser JC, et al：Serotonin1A receptors are increased in post-mortem prefrontal cortex in schizophrenia. Brain Res 708：209-214, 1996

52) Sumiyoshi T, Matsui M, Nohara S, et al：Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 58：1722-1725, 2001

53) Sumiyoshi C, Sumiyoshi T, Roy A, et al：Atypical antipsychotic drugs and organization of long-term semantic memory：Multidimensional scaling and cluster analysis of category fluency performance in schizophrenia. Int J Neuropsychopharmacol 9：677-683, 2006

54) Sumiyoshi T, Higuchi Y, Matsui M, et al：Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31：965-967, 2007

55) Sussman N：Anxiolytic antidepressant augmentation. J Clin Psychiatry 59(Suppl 5)：42-48, 1998

56) 武田俊彦：リスペリドン，ペロスピロン，クエチアピン，オランザピンはどこが違うのか．臨精医 34：405-414，2005

57) Tanda G, Frau R, Di Chiara：Local 5HT3 mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacol(Berlin) 119：15-19, 1995

58) Tanda G, Carboni E, Frau R, et al：Increase of extracellular dopamine in the prefrontal cortex：A trait of drugs with antidepressant potential?　Psychopharmacol(Berlin) 115：285-288, 1994

59) 寺尾岳：セロトニン受容体作用薬と抗うつ薬併用療法．臨精薬理 3：1395-1407，2000

受容体アゴニストによる治療効果―症例報告―．第18回日本臨床精神神経薬理学会・第38回日本神経精神薬理学会合同年会プログラム・抄録集．p142，2008

autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacol 34：495-499, 1995

62) Wedzony K, Chocyk A, Kolasiewicz W, et al：Glutamatergic neurons of rat medial prefrotal cortex innervating the ventral tegmental area are positive for serotonin 5-HT 1A receptor protein. J Physiol Pharmacol 58：611-624, 2007

63) Weinberger DR：Pharmacological mechanism of atypical antipsychotic drugs．臨精薬理 7：232-248，2004

64) Yocca F, Iben L, Meller E：Lack of apparent receptor reserve at postsynaptc 5-hydroxytryptamine 1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes. Mol Pharmacol 41：1066-1072, 1992

65) Yoshino T, Nisijima K, Katoh S, et al：Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A)receptors in the rat medial frontal cortex. Neurochem Int 40：355-360, 2002